European Commission approval for Verquvo to treat symptomatic chronic heart failure in adult patients with reduced ejection fraction – Bayer + Merck Inc.

Merck Inc., has announced that the European Commission (EC) has granted marketing authorization in the European Union (EU) for soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat).

In the EU, Verquvo (2.5 mg, 5 mg, and 10 mg) is indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous (IV) therapy.

Verquvo is being jointly developed by Merck and Bayer AG. Merck Inc., has the commercial rights to Verquvo in the United States and Bayer has the exclusive commercial rights in the rest of world.